Latham & Watkins advises WestView Capital Partners in its investment in Hubstaff WestView Capital Partners made a strategic investment in Hubstaff as the workforce management software company capitalizes...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Pionyr on the sale. Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena) and Pionyr Immunotherapeutics, Inc. have announced the closing of Ikena’s acquisition of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell and Paul Hastings LLP are advising Francisco Partners and TPG, and Latham & Watkins LLP is advising New Relic on the transaction....
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Cadence, and Wilson Sonsini Goodrich & Rosati advised Rambus on the transaction. Cadence Design Systems, Inc. and Rambus Inc. announced that they have entered...
You must be a Standard 1 Year member to access this content.
Cahill represented the lead arrangers in the financing. Fortrea Holdings announced a $500,000,000 term A credit facility, a $570,000,000 term B credit facility and a $450,000,000...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises Alpha II and existing shareholder WestView Capital Partners on TA Associates strategic Growth investment. TA Associates, a leading global private equity firm,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises NextRoll in US$50 million financing deal from Capital IP. NextRoll, the San Francisco-based marketing technology company delivering products for ambitious marketers to...
You must be a Standard 1 Year member to access this content.
Latham & Watkins Advises Guardant Health in Pricing of Upsized Public Offering of Common Stock. Guardant Health, Inc., a leading precision oncology company, has announced the pricing...
You must be a Standard 1 Year member to access this content.
Proskauer Rose advised Intapp, Latham & Watkins advised the underwriters, Sidley Austin advised Great Hill Equity Partners IV, L.P. and its affiliates, and Morrison & Foerster...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Coherus BioSciences, and Davis Polk advised J.P. Morgan Securities LLC and Citigroup Global Markets Inc. on the offering. Coherus BioSciences, Inc. (“Coherus”, Nasdaq:...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...
You must be a Standard 1 Year member to access this content.
